Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Until today this year the stock’s price performance recorded an increase of 20.08%. However, over the last six months, the performance has been weaker by 21.16%. The price of ABT increased 8.63% over the last 30 days. And in the last five days, it has surged by 4.33%.
Abbott Laboratories’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $136.59 on 02/24/25 and a low of $99.71 for the same time frame on 07/18/24.
52-week price history of ABT Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Abbott Laboratories’s current trading price is -0.56% away from its 52-week high, while its distance from the 52-week low is 36.22%. The stock’s price range during this time has been between $99.71 and $136.59. The trading volume for the Healthcare sector company’s shares reached about 6.39 million for the day, which was higher than the average daily volume of 5.79 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Abbott Laboratories (ABT) has experienced a quarterly rise of 17.16% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 235.56B and boasts a workforce of 114000 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 118.69, with a change in price of +21.81. Similarly, Abbott Laboratories recorded 5,565,573 in trading volume during the last 100 days, posting a change of +19.13%.
ABT’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ABT stands at 0.32. Similarly, the long-term debt-to-equity ratio is also 0.28.
ABT Stock Stochastic Average
Today’s raw stochastic average for Abbott Laboratories over the last 50 days is 97.01%.This indicates a increase from the raw stochastic average of the past 20 days, which was 92.73%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 91.42% and 94.22%, respectively.
